%0 Journal Article
%T Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study
%A Lisa F Potts
%A Alex C Cambon
%A Owen A Ross
%A Rosa Rademakers
%A Dennis W Dickson
%A Ryan J Uitti
%A Zbigniew K Wszolek
%A Shesh N Rai
%A Matthew J Farrer
%A David W Hein
%A Irene Litvan
%J BMC Medical Genetics
%D 2012
%I BioMed Central
%R 10.1186/1471-2350-13-16
%X DNA from 553 autopsy-confirmed Caucasian PSP cases (266 females, 279 males; age at onset 68 ¡À 8 years; age at death 75 ¡À 8) from the Society for PSP Brain Bank and 425 clinical control samples (197 females, 226 males; age at draw 72 ¡À 11 years) from healthy volunteers were genotyped using Taqman PCR and the SequenomiPLEX Gold assay.The proportion of NAT2 rapid acetylators compared to intermediate and slow acetylators was larger in cases than in controls (OR = 1.82, p < 0.05). There were no allelic or genotypic associations with PSP for any other SNPs tested with the exception of MAPT (p < 0.001).Our results show that NAT2 rapid acetylator phenotype is associated with PSP, suggesting that NAT2 may be responsible for activation of a xenobiotic whose metabolite is neurotoxic. Although our results need to be further confirmed in an independent sample, NAT2 acetylation status should be considered in future genetic and epidemiological studies of PSP.Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian disorder. Classically, patients present with progressive postural instability and falls followed by slow and hypometric vertical saccades and eventually vertical supranuclear gaze palsy.Neuropathologically, PSP is characterized by deposits of four-repeat microtubule associated protein tau (encoded by the MAPT gene) aggregates in neurons and glia of the basal ganglia and brain-stem [1]. Additionally, there is mitochondrial dysfunction, decreased ATP levels and inflammation in the brains of PSP patients [2-4]. The MAPT H1 haplotype has been consistently reported to be associated with PSP; however, it is also common in the general population, suggesting that gene-gene or gene-environment interactions are likely required for the development of this disease [5,6]. Recently, MAPT H1 was also associated with risk of Parkinson's disease (PD) suggesting shared pathways of disease [7]. Early-onset PD and PSP can present with a similar phenotype and be misdiagn
%K Progressive supranuclear palsy (PSP)
%K N-acetyltransferase 2 (NAT2)
%K Tauopathy
%K Single nucleotide polymorphisms (SNPs)
%K Parkinson's disease (PD)
%U http://www.biomedcentral.com/1471-2350/13/16